NRX Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
NRX Pharmaceuticals, Inc. (NRXP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.55 per share for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-15.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2022-08-15
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-06-30 was $1.55, a 89.17% decline year-over-year.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $2.27, a 77.30% decline year-over-year.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-09-30 was $9.80, a 15.66% decline year-over-year.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-06-30 was $14.31, a 1044.80% increase year-over-year.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $16.57, a 20.07% increase from fiscal 2020.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $13.80.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2022-06-30 | $1.55 10-Q · filed 2022-08-15 | $0.16 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | $2.27 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $16.57 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $9.80 10-Q/A · filed 2022-08-12 | $16.53 10-Q/A · filed 2022-08-12 | ||
| 2021-06-30 | $14.31 10-Q · filed 2022-08-15 | $18.37 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $10.00 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $13.80 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $11.62 10-Q/A · filed 2022-08-12 | $4.44 10-Q/A · filed 2022-08-12 | ||
| 2020-06-30 | $1.25 10-Q/A · filed 2022-08-12 | $1.25 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |